Vinorelbine
Carcinoma, Bronchogenic
University of Turin, ItalyPhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 89/ 100
Competitive context
8 Active assets in the Carcinoma, Bronchogenic cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin Nanfang Hospital, Southern Medical University | Phase 3 | BB |
Pralsetinib, trans- Hoffmann-La Roche | Phase 3 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II Nanfang Hospital, Southern Medical University | Phase 3 | BB |
Docetaxel University of Turin, Italy | Phase 3 | B |
Pembrolizumab Hoffmann-La Roche | Phase 3 | B |
View all 18 →
Same molecule, other indications
Vinorelbine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →